Arrayjet and Chemspace have agreed a partnership to augment and streamline Chemspace’s small molecule microarray (SMM) service offering.
Chemspace’s compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for assay development, contract screening and contract array manufacturing.
SMMs enable high-throughput screening of compound libraries against targets of interest. Compounds can be printed neat at 10mM in dimethyl sulfoxide (DMSO), and a unique data point is generated per target-ligand interaction. The technique is suited for targeting proteins and structured RNA, developing heterobifunctional degrader molecules (e.g., PROTAC), and training AI drug discovery models.
With this new collaboration, Arrayjet’s SMM customers will now be able to access Chemspace’s catalogue of 11.5 billion compounds, deep library annotation and ready-designed panels sorted by different molecule types and target groups.
Dr Adam Buckle, Chief Scientific Officer of Arrayjet, commented: “We’re seeing major growth in demand for new screening methodologies, particularly for difficult targets such as complex RNA structures previously thought to be undruggable. Small molecule microarrays have emerged as an effective solution for high-throughput hit-detection and hold huge potential in this space.”
Dr Yurii Moroz, Chief Executive Officer of Chemspace, added: “We are very happy that Arrayjet has chosen to work with Chemspace libraries as part of its small molecule microarray services. As new drug discovery developments, such as AI-powered approaches, advance, we anticipate the demand for comprehensive, commercial compound-screening solutions, such as SMM, to grow rapidly, and Arrayjet is well-positioned to provide these to researchers.”
